Sutro Biopharma/$STRO
1D1W1MYTD1Y5YMAX
About Sutro Biopharma
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
- Ticker
- $STRO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 128
- Headquarters
- South San Francisco, United States
- Website
- www.sutrobio.com
Sutro Biopharma Metrics
BasicAdvanced
$356M
-
-$15.47
1.51
-
Price and volume
Market cap
$356M
Beta
1.51
52-week high
$43.85
52-week low
$7.15
Average daily volume
300K
Financial strength
Current ratio
3.32
Quick ratio
3.216
Long term debt to equity
-3.991
Total debt to equity
-10.437
Interest coverage (TTM)
-3.17%
Profitability
EBITDA (TTM)
-125.795
Gross margin (TTM)
-216.71%
Net profit margin (TTM)
-395.25%
Operating margin (TTM)
-288.52%
Effective tax rate (TTM)
0.05%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-36.08%
Return on equity (TTM)
266.76%
Valuation
Price to revenue (TTM)
5.477
Price to book
-3.44
Price to tangible book (TTM)
-3.44
Price to free cash flow (TTM)
-1.719
Free cash flow yield (TTM)
-58.18%
Free cash flow per share (TTM)
-12.473
Growth
Revenue change (TTM)
-56.25%
Earnings per share change (TTM)
-37.64%
3-year revenue growth (CAGR)
-7.03%
3-year earnings per share growth (CAGR)
-14.77%
Sutro Biopharma News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.